Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Metabolic Syndrome and Endometrial Cancer Survival
EF 2018-19
Résumé
For women in Canada, endometrial cancer is the fourth most commonly diagnosed cancer with 7,300 cases diagnosed annually and 1,150 women expected to die from this cancer in 2018. Between 2000 and 2010, Canadian endometrial cancer survival rates decreased 1% annually and women living with obesity, diabetes and/or high blood pressure had less favorable outcomes. Yet, the combined effect of these risk factors on endometrial cancer survivorship is still not well understood. The Metabolic Syndrome (MetS) is the clustering of risk factors including high blood pressure, blood glucose, central adiposity, abnormal cholesterol and triglycerides. To date, only one previous study has explored the effects of the MetS on endometrial cancer survival and reported that women with MetS had 1.56 times the risk of dying from endometrial cancer compared to those who did not have this syndrome. We have identified an association between MetS and endometrial cancer risk. There is biologic plausibility that MetS could also be associated with survival, which remains to be tested. The current study aims to examine the impact of MetS on survival outcomes in endometrial cancer survivors, primarily cancer recurrence, endometrial cancer-specific survival and all-cause mortality. A secondary aim is to examine the association between each component of MetS on these survival outcomes. It is important to identify opportunities to intervene in this population given the decreasing endometrial cancer-specific survival rates. This research will provide additional evidence needed to develop and assess interventions in endometrial cancer survivors targeting early indicators of cardiovascular and metabolic disease, such as MetS, with the ultimate aim of improving endometrial cancer survival.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406607
Name
Kokts-Porietis Renee
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Metabolic Syndrome and Endometrial Cancer Survival
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cohort Study; Endometrial Cancer; Epidemiology; Female; Hypertension; Metabolic Syndrome; Neoplasms; Obesity; Population Health; Survival
Abstract
For women in Canada, endometrial cancer is the fourth most commonly diagnosed cancer with 7,300 cases diagnosed annually and 1,150 women expected to die from this cancer in 2018. Between 2000 and 2010, Canadian endometrial cancer survival rates decreased 1% annually and women living with obesity, diabetes and/or high blood pressure had less favorable outcomes. Yet, the combined effect of these risk factors on endometrial cancer survivorship is still not well understood. The Metabolic Syndrome (MetS) is the clustering of risk factors including high blood pressure, blood glucose, central adiposity, abnormal cholesterol and triglycerides. To date, only one previous study has explored the effects of the MetS on endometrial cancer survival and reported that women with MetS had 1.56 times the risk of dying from endometrial cancer compared to those who did not have this syndrome. We have identified an association between MetS and endometrial cancer risk. There is biologic plausibility that MetS could also be associated with survival, which remains to be tested. The current study aims to examine the impact of MetS on survival outcomes in endometrial cancer survivors, primarily cancer recurrence, endometrial cancer-specific survival and all-cause mortality. A secondary aim is to examine the association between each component of MetS on these survival outcomes. It is important to identify opportunities to intervene in this population given the decreasing endometrial cancer-specific survival rates. This research will provide additional evidence needed to develop and assess interventions in endometrial cancer survivors targeting early indicators of cardiovascular and metabolic disease, such as MetS, with the ultimate aim of improving endometrial cancer survival.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kokts-Porietis, Renee
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~